Drug-trial center falls to trends - Indianapolis Star bi13511348 The Money Times Drug-trial center falls to trends Indianapolis Star, United States - 16 hours ago By Erika D. Smith When the Lilly Center for Medical Science ends trials Indianapolis later year, be the end of an era at Eli Lilly Covance buys Eli Lilly facility 10-year deal Forbes UPDATE 1-Lilly farms out some lab services to Covance Reuters Drug giant Lilly transferring trial monitoring to Local Tech Wire newratings.com - Pharma Times (subscription)all 93 news articles..

We need cancer drugs. NICE must go - Times Online bi13511348 ITV.com We need cancer drugs. NICE must go Times Online, UK - 1 hour ago NICE was set up 1999 a brief to provide guidelines and technology assessments for England and Wales (there a separate panel for Surgery 'saves more lives from cancer than drugs' Telegraph.co.uk Nice has got prescription wrong guardian.co.uk UK Says Kidney Cancer Drugs Aren?t Worth the Cost Wall Street Journal Blogs The Press Association - BBC Newsall 261 news articles..

Supervisor Chaplain Clinical Pastoral Education - Spiritual Care - Seattle Times bi13511348 Supervisor Chaplain Pastoral Education - Spiritual Care Seattle Times, United States - 11 minutes ago This a regular, salaried, Day shift position, 0.6 FTE, 24 hours per week. This position eligible for benefits. Provide spiritual and emotional care to ..

Affymax Announces Favorable Data Monitoring Committee Review of - MarketW bi13511348 Affymax Announces Favorable Data Monitoring Committee Review of MarketWatch - 2 hours ago Affymax conducting Phase 3 trials for Hematide to treat anemia associated chronic renal failure and Takeda initiated a Phase 1 ..

US Renal Care Appoints Chief Medical Officer - MarketWatch bi13511348 US Renal Care Appoints Chief Medical Officer MarketWatch - 6 hours ago During time he oversaw all program development and helped grow the Company from 37 facilities the US to more than 500 internationally. ..

New Prostate Cancer Test Ready for Commercialization Following - Marke bi13511348 OverTheLimit.info New Prostate Cancer Test Ready for Commercialization Following MarketWatch - 8 hours ago today announced that HDC's new gene-based molecular diagnostic test for prostate cancer has now successfully completed it's Phase III double-blind Prostate cancer rate spurs campaigners So Md News Task Force Says Men Age 75 and Older Should Not Be Screened For Earthtimes (press release) USPSTF Recommends Against Prostate Cancer Screening Men 75 Medscape (subscription) Forbes - MedPage Todayall 787 news articles..

Enrollment of Breast and Ovarian Cancer Patients Commenced for - MarketWatch bi13511348 Enrollment of Breast and Ovarian Cancer Patients Commenced for MarketWatch - 8 hours ago Currently the AE37 vaccine the subject of a Phase II trial patients breast cancer and a Phase I trial prostate cancer patients. Enrollment of Breast and Ovarian Cancer Patients Commenced for RedOrbit all 7 news articles..

CLX Medical, Inc. Announces Results of Meetings at AACC Annual - MarketWatch bi13511348 CLX Medical, Inc. Announces Results of Meetings at AACC Annual MarketWatch - 8 hours ago AACC's Lab Expo, the largest gathering of laboratory industry companies the world, was anticipated to include 1800 booths and 650 exhibitors. ..

Praxis Launches Patient Recruitment Campaign For 2nd Protocol of - Market bi13511348 Praxis Launches Patient Recruitment Campaign For 2nd Protocol of MarketWatch - 6 hours ago According to David Fox, President and CEO of Praxis, "This a significant study the women's health area, and our expertise and strategic ..

Cyclacel to Present At the Canaccord Adams Global Growth Conference - MarketW bi13511348 Earthtimes (press release) Cyclacel to Present At the Canaccord Adams Global Growth Conference MarketWatch - 4 hours ago Three orally-available Cyclacel drugs are development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, Phase 2 studies La Jolla Pharmaceutical Company to Present at Canaccord Adams WELT ONLINE Delcath Systems to Present at the 28th Annual Canaccord Adams MarketWatch Cell Genesys to Present at the 28th Annual Canaccord Adams Global MarketWatch MarketWatch - MarketWatchall 370 news articles..

(OTC: CLXN) CLX Medical Reaches Agreement With European - Stockhouse bi13511348 (OTC: CLXN) CLX Medical Reaches Agreement With European Stockhouse, Canada - 2 hours ago CLX Medical, Inc. (OTCBB: CLXN) announced today Positive Results of meetings at American Association for Chemistry (AACC) Annual Meeting and ..

For Lab Automation Systems, Being Open Is Better - MarketWatch bi13511348 For Lab Automation Systems, Being Open Is Better MarketWatch - 4 hours ago New technologies based on manufacturing automation have been transforming hospital laboratories and corporate drug development laboratories ever ..

Metabasis Therapeutics Announces Second Quarter 2008 Results and - Centre bi13511348 Metabasis Therapeutics Announces Second Quarter 2008 Results and Centre Daily Times, PA - 1 hour ago The decreases for the quarter and six-month period were mainly due to decreased development costs for MB07803, MB07133 and MB07811 and stock-based Inhibitex Reports Initiation of Multiple Ascending Dose Trial of PharmaLive.com (press release) all 3 news articles..

Honda Cbr Accessories - Home